CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Berlin, Germany and 319 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Berlin, Germany and 144 other locations
with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with 2:1 randomization into Ar...
Phase 2
Berlin, State of Berlin, Germany and 35 other locations
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-...
Phase 3
Berlin, State of Berlin, Germany and 257 other locations
(BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-base...
Phase 3
Berlin, Germany and 80 other locations
This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with r...
Phase 4
Berlin, Germany and 51 other locations
growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine ...
Phase 3
Berlin, Germany and 292 other locations
elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse.During the ctDNA screening pha...
Phase 3
Potsdam, Germany and 111 other locations
treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.HR-positive breast cancer cells have...
Phase 3
Berlin, Germany and 205 other locations
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy a...
Phase 3
Berlin, Germany and 483 other locations
Clinical trials
Research sites
Resources
Legal